期刊文献+

舒尼替尼治疗晚期三阴性乳腺癌临床获益1例

下载PDF
导出
摘要 乳腺癌是女性最常见的恶性肿瘤,随着个体化治疗理念的形成和推广,乳腺癌的死亡率呈下降趋势。三阴性乳腺癌(triple—negativebreastcancer,TNBC)是一种侵袭性很强的乳腺癌亚型,预后较差。目前对于TNBC术后复发患者主要的治疗手段仍是全身化疗。随着分子靶向治疗时代的到来,更多的靶向治疗药物应用于临床并取得了很好的疗效。本文对解放军307医院乳腺肿瘤科收治的1例经3个联合化疗方案无效后采用苹果酸舒尼替尼治疗,并取得临床获益的TNBC患者的临床资料进行分析。
机构地区 解放军
出处 《中国癌症杂志》 CAS CSCD 北大核心 2012年第7期552-553,共2页 China Oncology
  • 相关文献

参考文献5

  • 1GOLDHIRSCH A, WOOD W C, COATES A S, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [ J ] . Ann Oncol, 2011, 22(8): 1736-1747.
  • 2姚舒洋,徐兵河.三阴性乳腺癌的分子靶向治疗[J].临床药物治疗杂志,2011,9(1):25-30. 被引量:10
  • 3HAMILTON E P, BLACKWELL K L. Safety of bevacizumab in patients with metastatic breast cancer [ J ] .Oncology, 2011, 80(5-6): 314-325.
  • 4FRATTO M E, IMPERATORI M, VINCENZI B, et al. New perspectives: role of Sunitinib in breast cancer [ J ] . 2011, 162(3): 251-257.
  • 5中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:268

二级参考文献39

  • 1Burstein HJ,Elias AD,Rugo HS,et al.Phase Ⅱ study of sunitinib malate,an oral multitargeted tyrosine kinase inhibitor,in patients with metastatic breast cancer previously treated with an anthracycline and a taxane[J].J Clin Oncol,2008,26:1810-1816.
  • 2Baselga J,Roche H,Costa F,et al.SOLTI-0701:A Multinational Double-Blind,Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC)[J].Cancer Research,2009,69:497S-497S.
  • 3Gradishar WJ,Kaklamani V,Sahoo TP,et al.A Double-Blind,Randomized,Placebo-Controlled,Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer[J].Cancer Research,2009,69:496S-496S.
  • 4Burris HA,Ⅲ,Hurwitz HI,Dees EC,et al.Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib (GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23:5305-5313.
  • 5Burstein HJ,Storniolo AM,Franco S,et al.A phase Ⅱ study of lapatinib monotherapy in chemotherapy-refractory HER-2 -positive and HER-2-negative advanced or metastatic breast cancer[J].Ann Oncol,2008,19:1068-1074.
  • 6Green MD,Francis PA,Gebski V,et al.Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer[J].Ann Oncol,2009,20:1813-1817.
  • 7von Minckwitz G,Jonat W,Fasching P,et al.A multicentre phase Ⅱ study on gefitinib in taxane-and anthracycline -pretreated metastatic breast cancer[J].Breast Cancer Res Treat,2005,89:165-172.
  • 8Dickler MN,Cobleigh MA,Miller KD,et al.Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer[J].Breast Cancer Res Treat,2009,115:115-121.
  • 9Dickler MN,Rugo HS,Eberle CA,et al.A phase Ⅱ trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer[J].Clin Cancer Res,2008,14:7878-7883.
  • 10Finn RS,Dering J,Ginther C,et al.Dasatinib,an orally active small molecule inhibitor of both the src and abl kinases,selectively inhibits growth of basal-type/" triple-negative" breast cancer cell lines growing in vitro[J].Breast Cancer Res Treat,2007,105:319-326.

共引文献275

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部